Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Theravance Biopharma, Inc.

Get SEC filing alerts via email and in your feed for Theravance Biopharma, Inc.

TBPH

Theravance Biopharma, Inc.

About Theravance Biopharma, Inc.

Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines for respiratory and neurological conditions. Its key products include YUPELRI for COPD and investigational therapies like ampreloxetine for neurogenic orthostatic hypotension in MSA patients. The company leverages strategic partnerships, patent protections, and a diversified development pipeline to deliver innovative treatments and create shareholder value.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Theravance Biopharma, Inc.

1
1
Theravance Biopharma, Inc. Theravance Biopharma Reports 15% Revenue Growth and Improved Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Theravance Biopharma, Inc. Theravance Biopharma Reports $105.9M Net Income in 2025, Driven by TRELEGY Royalty Sale

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Theravance Biopharma, Inc. Theravance Biopharma Reports 19% Revenue Growth and Net Income Turnaround in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Theravance Biopharma, Inc. Theravance Biopharma Reports 84% Revenue Growth and $54.8M Net Income in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Theravance Biopharma, Inc. Theravance Biopharma Reports 6% Revenue Growth to $15.4 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Theravance Biopharma, Inc. Theravance Biopharma Reports $56.4 Million Net Loss and 12% Revenue Growth for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Theravance Biopharma, Inc. Theravance Biopharma Reports 7% Revenue Growth, Net Loss Widens in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments